| CAS NO: | 12650-69-0 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 100mg | 电议 |
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 500.62 |
| Cas No. | 12650-69-0 |
| Formula | C26H44O9 |
| Solubility | ≥100 mg/mL in DMSO; insoluble in H2O; ≥5.69 mg/mL in EtOH |
| Chemical Name | 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid |
| Canonical SMILES | O[C@@H]1[C@H](CO[C@@H](C/C(C)=C/C(OCCCCCCCCC(O)=O)=O)[C@@H]1O)C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
Mupirocin is an antibiotic that inhibits isoleucyl-tRNA synthetase in bacterial cell walls, weakening the growth of bacteria with an MIC value of 0.05 μg/ml in Staphylococcus aureus.It is mainly used as an antibacterial agent against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).
MRSA can resist therapeutic treatment via causing chronic infections leading to high rate mortality, by causing a proteic biofilm, extracellular DNA or carbohydrate matrix that allows bacterial survival in unfavourable environments.
Because of the similarity between isoleucine and the antibiotics's epoxy side chain, Mupirocin can prevent the conversion of isoleucine and tARN to isoleucine-charged transfer RNA by binding the active centre of isoleucyl-tRNA syntethase and thus decreasing its cellular levels inside the cells, causing bacterial death.
Mupirocin is a strong acid as a form of a crystalline white powder, freely soluble in dichloromethane and acetone, slightly soluble in water. Its antibiotic activity is pH dependent, at pH between 4 and 9 in aqueous solutions, the activity is maintained; but outside this interval, molecular rearrangements occur with the formation of two isomers, without interconversion. Mupirocin is the most widely used topical antibiotic to control the MRSA outbreaks, for infections of soft tissue or skin and for nasal decolonization.
References:
1. Tucaliuc A, Blaga AC, Galaction AI, Cascaval D. Mupirocin: applications and production. Biotechnol Lett. 2019 May;41(4-5):495-502. doi:10.1007/s10529-019-02670-w. Epub 2019 Mar 29. Review. PubMed PMID: 30927135.
2. Khoshnood S, Heidary M, Asadi A, Soleimani S, Motahar M, Savari M, Saki M, Abdi M. A review on mechanism of action, resistance, synergism, and clinical implications of mupirocin against Staphylococcus aureus. Biomed Pharmacother. 2019 Jan; 109:1809-1818. doi: 10.1016/j.biopha.2018.10.131. Epub 2018 Nov 26.Review. PubMed PMID: 30551435.
3. Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance: clinical implications and potential alternatives for the eradication of MRSA. J Antimicrob Chemother. 2015 Oct;70(10):2681-92. doi: 10.1093/jac/dkv169. Epub 2015 Jul 3. Review. PubMed PMID: 26142407.
4. Hughes J, Mellows G. Inhibition of isoleucyl-transfer ribonucleic acid synthetase in Escherichia coli by pseudomonic acid. Biochem J. 1978 Oct 15;176(1):305-18. PubMed PMID: 365175; PubMed Central PMCID: PMC1186229.
m.cnreagent.com